Skip to content
DataLookout
Menu

NCT06836232

An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Oct 10, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.

All 15 versions: 13 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 19 → 28 locations
  2. Minor Study sites revised (20)
  3. Minor Study sites: 19 to 20
  4. Notable Eligibility criteria expanded, about 10 words
    • Study sites: 18 to 19
  5. Minor Study sites: 17 to 18v11
  6. Notable Primary and study completion pushed from Oct 2026 to Oct 2027
    • Trial arms changed: 3 → 5
    • Study sites: 16 to 17
    • Interventions: VTX2735 (Drug), VTX2735 (Drug), VTX2735 (Drug) to VTX2735 (Drug), VTX2735 (Drug), VTX2735 (Drug), VTX2735 (Drug), VTX2735 (Drug)
    v10
  7. Minor Study sites: 15 to 16v8
  8. Notable Enrollment target: 30 to 50v7 Show 5 more changesShow less
    • Primary and study completion dates: Jan 2026 to Oct 2026
    • Eligibility criteria revised
    • Study sites: 14 to 15
    • Interventions: VTX2735 (Drug) to VTX2735 (Drug), VTX2735 (Drug), VTX2735 (Drug)
    • Study arms: 1 to 3
  9. Minor Study sites: 10 to 14v6
  10. Minor Study sites: 8 to 10v5
  11. Minor Study sites: 6 to 8v4
  12. Minor Study sites: 3 to 6v3
  13. Minor Study sites: 2 to 3v2
  14. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Safety and tolerability of VTX2735
Timeframe: Day 1 of treatment period through study completion, up to 26 weeks

Secondary (2)

Effect of VTX2735 on pericardial pain
Effect of VTX2735 on inflammation

Arms and interventions

Cohort AExperimental
Cohort B Treatment Group B1Experimental
Cohort B Treatment Group B2Experimental
Cohort C Treatment Group C1Experimental
Cohort C Treatment Group C2Experimental

Drugs: VTX2735

Sites

28 sites in 7 countries

United States 15, France 4, Belgium 2, Canada 2, Greece 2, Spain 2, United Kingdom 1